K H van der Velden

Publications (2)1.23 Total impact

• Article: Intravitreale Implantate

  S. Winterhalter, P. Ruokonen, K.H. van der Velden, U. Pleyer, A.M. Joussen
  [show abstract] [hide abstract]
  ABSTRACT: Für die Therapie der nichtinfektiösen Uveitis werden Immunsuppressiva verwendet, sofern keine ausreichende Reiz- und Rezidivfreiheit mit Steroiden in niedriger Dosierung zu erreichen ist. Hierbei werden zum Erhalt des Visus auch bei Erkrankungen, die auf die Augen beschränkt sind, zum Teil erhebliche Nebenwirkungen in Kauf genommen. Wünschenswert ist also eine Therapie, die hochwirksam ist, auf die Augen beschränkt bleibt und ein geringes Nebenwirkungspotenzial aufweist. Hierzu wurden die Fluocinolon-acetonid- und Dexamethason-Implantate entwickelt. Dexamethason-Implantate sind bereits für die Therapie von retinalen Venenverschlüssen zugelassen und werden hier erfolgreich eingesetzt. Das diabetische Makulaödem ist ein weiteres mögliches Einsatzgebiet für Dexamethason-Implantate. Immunosuppressive agents are used for the therapy of noninfectious uveitis if intraocular quiescence and freedom from recurrences are not achievable with oral steroids at a low dosage. Partially, severe side effects are tolerated to preserve visual acuity even if the disease is limited to the eyes. Because of this a therapy would be desirable which is highly effective, limited to the eyes and with few side effects. For this fluocinolone acetonide and dexamethasone drug delivery systems were developed. Dexamethasone implants were already approved for the therapy of retinal vein occlusions and are used successfully. Diabetic macular edema would be another possible indication for dexamethasone implants. SchlüsselwörterDexamethason-Implantat–Fluocinolon-acetonid-Implantat–Makulaödem–Retinaler Venenverschluss–Uveitis KeywordsDexamethasone drug delivery system–Fluocinolone acetonide implant–Macular edema–Retinal vein occlusion–Uveitis
  Der Ophthalmologe 05/2012; 108(3):222-229. · 0.62 Impact Factor
• Article: [Intravitreal implants: drug carriers and carriers of hope?].

  S Winterhalter, P Ruokonen, K H van der Velden, U Pleyer, A M Joussen
  [show abstract] [hide abstract]
  ABSTRACT: Immunosuppressive agents are used for the therapy of noninfectious uveitis if intraocular quiescence and freedom from recurrences are not achievable with oral steroids at a low dosage. Partially, severe side effects are tolerated to preserve visual acuity even if the disease is limited to the eyes. Because of this a therapy would be desirable which is highly effective, limited to the eyes and with few side effects. For this fluocinolone acetonide and dexamethasone drug delivery systems were developed. Dexamethasone implants were already approved for the therapy of retinal vein occlusions and are used successfully. Diabetic macular edema would be another possible indication for dexamethasone implants.
  Der Ophthalmologe 03/2011; 108(3):222-9. · 0.62 Impact Factor